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AortaA B S T R A C T
A live, attenuated form of Mycobacterium bovis, bacillus Calmette–Gue´rin (BCG), is com-
monly used as intravesical immunotherapy for non-invasive urothelial bladder carcinoma.
While complications are rare, dissemination can occur. A case of mycotic aortic aneurysm
following BCG administration with recovery of Mycobacterium bovis in culture is reported. A
review of the published experience with this problem is also presented.
 2013 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.1. Case report
A 64-year-old man presented to our hospital with a four-week
history of progressive back pain that began six weeks after he
underwent extensive dental work. His past medical history
included gastroesophageal reflux disease, asthma, ten pack-
years of smoking, and high-grade bladder cancer that had
been treated with bacillus Calmette–Gue´rin (BCG), the live,
attenuated form of Mycobacterium bovis, five months previ-
ously. On admission, his body temperature was 36.5 C; car-
diovascular and abdominal exams were normal and withoutbruits. There was no tenderness over the thoracic and lumbar
spines. Initial laboratory testing demonstrated a white blood
cell count of 6.0 · 103/cu mm (reference 4.5–11.0 · 103/cu
mm); a chemistry panel was within reference ranges. Com-
puted tomographic (CT) scans of the chest, abdomen, and pel-
vis revealed a large, proximal aortic aneurysm (8.4 cm in
transverse diameter) beginning at the level of the diaphrag-
matic crus, with an associated lobulated, saccular outpou-
ching arising from the proximal abdominal aorta (Fig. 1). A
psoas muscle abscess was contiguous with the posterior infe-
rior margin of the aneurysm (Fig. 2).ved.
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Fig. 1 – Image of the suprarenal aortic aneurysm (8.4 cm
transverse diameter) with associated saccular outpouching
[(4.7 cm cephalocaudal · 2.2 cm anteroposterior · 3.7 cm
transverse diameter), white arrows] using 3-dimensional
CT angiography: (A) sagittal view, (B) coronal view.
Fig. 2 – Image of psoas muscle abscess [(2.8 cm
cephalocaudal · 3.1 cm anteroposterior · 6.1 cm transverse
diameter), white arrow] using contrast-enhanced CT
angiography.
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bacilli (AFB), and a culture of fluid aspirated from the psoas
muscle collection were negative. Empiric treatment with
rifampin, isoniazid, pyrazinamide, and ethambutol (RIPE)
was initiated. Transthoracic echocardiography showed no
valve pathology. Surgical consultation was obtained, RIPE
was held for 72 h prior to surgery, and the patient underwent
open surgical debridement and repair with a 24-mm rifam-
pin-soaked, four-branched, Coselli vascular graft. The surgery
was performed with partial left heart bypass and distal aortic
perfusion. With this technique, the aorta could be clampedand extensively debrided, while perfusion to the kidneys
and lower extremities was maintained. Intraoperative exam-
ination revealed a contained rupture of the aorta surrounded
by turbid fluid. Malodorous fluid was also noted within the
left psoas muscle.
Cultures were collected for bacteria, fungi, and AFB from
the aortic tissue, periaortic fluid, left psoas muscle fluid,
and peripheral blood. Culture of the aortic tissue in Middle-
brook media demonstrated growth of an organism identified
as belonging to the M. tuberculosis complex by nucleic acid
probe testing (AccuProbe, Gen-Probe, San Diego, CA). The final
identification of BCG was obtained through high-performance
liquid chromatographic (HPLC) identification of the mycolic
acid profile (Sherlock, MIDI, Inc., Newark, DE).
RIPE therapy plus vitamin B6 was re-initiated post-opera-
tively; pyrazinamide was discontinued upon definitive identi-
fication of BCG. After three months of treatment, the patient
developed peripheral neuropathy that was attributed to isoni-
azid, so this agent was stopped and replaced with moxifloxa-
cin. One month later, he reported changes in his vision. He
was evaluated by ophthalmology due to concern for etham-
butol-associated optic neuritis. A diagnosis of cataracts was
made; treatment with moxifloxacin and rifampin was contin-
ued, but ethambutol was discontinued. Repeat CT imaging of
the chest and abdomen 6 months after surgery showed post-
surgical changes superior to the diaphragmatic hiatus with a
4.5 · 2.3 cm fluid collection within the right diaphragmatic
crus. Nine months after surgery, he developed posterior ankle
pain. Achilles tendinopathy was diagnosed one month later
and attributed to moxifloxacin. At that time, moxifloxacin
and rifampin were discontinued. Repeat CT imaging of the
chest and abdomen 10 months post-surgery was unchanged.
2. Discussion
Bacillus Calmette–Guerin is a live, attenuated strain of Myco-
bacterium bovis that was developed in the early 20th century
as a vaccine against tuberculosis. It is now widely used in
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adjuvant therapy for malignant melanoma [2,3]. While its
mechanism of action against bladder carcinoma is not fully
understood, use of BCG has been shown to induce a multifac-
eted inflammatory response that is thought to result in anti-
tumor effects [4].
Intravesical BCG instillation is associated with localized
reactions, including hematuria (30–35% of treated patients)
and lower urinary tract symptoms, such as urgency, fre-
quency, and dysuria (30–60%) [5]. Other local complications,
including granulomatous prostatitis and epididymo-orchitis
(1–4%), are less common, but compel cessation of treatment.
Systemic side effects, such as fever and malaise, are not
uncommon (10–30%), but are typically transient. Potentially
life-threatening complications are heralded by high, persis-
tent fever and are either due to sepsis or a systemic immune
response. Although uncommon (0–7%), these complications
can occur years following BCG instillation.
Vascular complications are rare, with only 24 cases previ-
ously reported (Table 1) [3,6–26]. While men are 3–4 times
more likely than women to develop urothelial bladder cancer
[27], only men have been reported to develop aneurysms after
urinary bladder BCG instillations. Although one case of a my-
cotic aneurysm occurring in a woman has been described,
this was in the setting of BCG therapy for metastatic malig-
nant melanoma [3].
The mean age of patients at the time of the mycotic aneu-
rysm diagnosis is 71 years, with individuals as young as
58 years reported [3,6–26]. The mean reported aneurysm size
is 5.2 cm in largest diameter, with a range of 1–8 cm. Mycotic
aneurysms commonly appear saccular and thin-walled on
radiographic imaging (Fig. 1) [6–11]. While vascular complica-
tions involving both large- and medium-sized vessels have
been reported, 79% of mycotic aneurysms associated with
BCG therapy have primarily involved the aorta. Of those 19
cases, one occurred at the aortic arch while the remaining
18 involved the abdominal aorta, and 15 occurred inferior to
the renal vasculature. Four (22%) of the 18 reported cases of
BCG-associated abdominal aortic aneurysms have been
accompanied by rupture, and all four ruptures occurred in pa-
tients with infrarenal aneurysms. Extension of the infection
into the psoas muscle occurred in 7 (39%) of 18 previously re-
ported patients with BCG-related abdominal aortic aneu-
rysms. These psoas muscle abscesses also occurred nearly
exclusively in patients with infrarenal mycotic aneurysms
(Table 1). The one notable exception is the case reported by
Izes et al., where the patient presented with an aneurysm of
the aortic arch and was subsequently noted to have an iso-
lated psoas muscle abscess [12].
As with other complications of intravesical BCG therapy,
mycotic aneurysms may come to attention long after treat-
ment has been administered. Cases diagnosed between four
months and over five years after completion of treatment
have been described [11,13]. Symptoms of BCG-related myco-
tic aneurysms are non-specific. Weight loss is the most com-
mon constitutional sign, occurring in 33% of cases, followed
by fever (20%) and night sweats (15%). In patients with site-
specific symptoms, lumbago was most frequent, occurring
in 8 (33%) of the previously reported cases, all of whom had
an infrarenal aneurysm. Due to the rarity of the condition,the non-specific symptoms, and the potential for late-onset
disease manifestations, a delay in accurate diagnosis of over
a year occurred in four cases [3,9,14,15]. One patient who pre-
sented with constitutional symptoms of malaise and general-
ized weakness, for example, was found to have an elevated
erythrocyte sedimentation rate and was presumptively diag-
nosed with polymyalgia rheumatica. Only after the develop-
ment of abdominal and back pain did a CT scan of the
abdomen lead to the definitive diagnosis [16]. Since bladder
cancer and aortic aneurysms tend to affect patients of similar
ages, the aortic aneurysm may be initially misjudged as inci-
dental [17].
Accurate identification of BCG in culture presents a diag-
nostic challenge. Many microbiology laboratories only speci-
ate these organisms to the level of the M. tuberculosis
complex using nucleic acid probe testing. Additional meth-
ods, such as biochemical testing for nitratase activity and
thiophen-2-carboxylic acid hydrazide susceptibility, HPLC
identification of the mycolic acid profile, and/or susceptibility
testing for pyrazinamide mono-resistance, are needed to dis-
tinguish M. tuberculosis from BCG. Molecular techniques have
also been developed, including multiplex PCR to detect dele-
tion of genomic region RD1 [28] and ETR-D spacer sequencing
[29]. However, these methods are not commercially available
and are not routinely performed in microbiology laboratories,
particularly in regions with a low prevalence of tuberculosis.
Thus, a high clinical index of suspicion based upon a history
of BCG instillation is necessary to guide laboratory identifica-
tion of the organism.
Treatment of BCG-related mycotic aneurysms has com-
monly involved combined antimycobacterial therapy with
surgical placement of rifampin-soaked aortic graft material.
Currently, there are no formal guidelines for the duration
and selection of antimicrobial treatment of BCG-associated
mycotic aneurysms; however, the most frequently utilized
regimen for reported cases includes a minimum of 9 months
of isoniazid and rifampin (Table 1). There is no role for pyra-
zinamide in the treatment of BCG-related infections because
of inherent resistance owing to a lack of pyrazinamidase
and nicotinamidase, enzymes necessary for activation of
the drug [30]. BCG is also susceptible to the fluoroquinolone
moxifloxacin in vitro [31] and has been employed with partial
success in previous cases where first-line agents were contra-
indicated [13] and [14].
Since BCG has been recovered in culture in a minority of
cases, the roles of host and pathogen in the formation of my-
cotic aneurysms remain unclear. Furthermore, BCG is not a
single entity, as multiple bladder instillation protocols using
different strains of BCG are currently utilized. While prior
studies have been designed to establish equivalent anti-
tumor efficacy among strains [32], recent research has eluci-
dated divergence between BCG strains, including differences
in antibiotic susceptibility patterns [33]. Further investigation
of relative virulence and risk of dissemination may guide
future therapy protocols.
This report expands the limited data on vascular compli-
cations related to BCG therapy. This case is unique in that it
is the first reported case where an aneurysm superior to the
renal vasculature was contiguous with a psoas muscle ab-
scess. Further, the three dimensional imaging presented here
Table 1 – Reported cases of BCG-related vascular complications.
Case Age Anatomical sitea Position Sizeb Rupture Presenting symptomsc Surgical repaird Antibiotic regimene Outcome
Woodsf,g 62 AA Infrarenal 4.5 cm No LBP Primary RI Lived
Bornetg 74 Bilateral FA N/A N/A Yes Rupture Primary RIE · 3 mo; IE · 9 mo Lived
Deresiewiczg 67 AA, EIA Infrarenal 8 cm No Pulsatile mass, WL Primary None Died
Izesg 69 Aortic Arch, PM N/A 5 cm No WL, Fatigue, Confusion None None Died
Wolfg 80 AA, PM Infrarenal NR Yes LBP, RDP, NS, malaise Primary RIE · 20 mo Lived
Hellingerg 71 AA, PM Lowerh 6 cm No Fever, malaise Primary RIE · 2 mo; IE · 10 mo Lived
Rozenblitg 76 AA, PM, OM Infrarenal NR No LBP, WL, RDP EVAR RIE + FQ Died
Dammg 71 AA Infrarenal NR Yes Abdominal pain, fever Primary RI Lived
Seeligg 72 Left FA bypass graft N/A N/A No Groin pain Primary RIE Lived
Seeligg 58 AA Infrarenal 6 cm No LBP, Fever, WL Primary IE · 12 mo Lived
Seeligg 71 AA Infrarenal 6 cm No Extremity wound, fever Primary RIE · 2 mo, RI · 10 mo Lived
Farberg 74 Left FA N/A N/A No Leg pain, pulsatile mass Primary ER Lived
LaBergeg 75 AA, PM Infrarenal NR No LBP Primary after EVAR NR NR
Geldmacherg 68 CA fistula N/A NR No Bleeding Primary NR NR
Kamphuisg 65 AA Suprarenal NR No AP, WL, Nausea Primary None Died
Witjesg 67 Left PA N/A NR No Fever, knee pain None RIE · 12 mo Lived
Wadag 75 AA, PM, Left FA Infrarenal 5 cm No LBP Primary None Lived
Dahlg 69 AA, PM, SP Infrarenal 4.5 cm Yes LBP, NS, RDP, Malaise Primary RI · 12 mo Lived
Hardingg 80 AA Infrarenal 7.6 cm Yes Fever, WL, Malaise Primary RIE · 12 mo Lived
Safdarg 79 AA Infrarenal 3 cm No Fever, NS, WL, Malaise Primary RIE · 12 mo Lived
Costiniukg 75 AA, FA NR 6.5 cm No LBP, AP Primary RIE · 12 mo Lived
Coscasg 79 Descending TA,
AA, Left EIA, Left PTA
Infrarenal 1 cm No Painful neck mass Primary RIE · 2 mo; RI · 7 mo Diedi
Maundrell 75 AA Suprarenal 5 cm No Fever, NS, WL Primary RIE Died
Santbergen 58 AA, PM, SP Infrarenal NR No LBP EVAR RI + FQ · 12 mo Lived
Present case 64 AA, PM Suprarenal 8.4 No LBP Primary R · 9 mo; FQ · 6 mo; E · 4 mo; I · 3 mo Lived
a AA: Abdominal Aorta; CA: Carotid Artery; EIA: External Illiac Artery; FA: Femoral Artery; OM: Osteomyelitis; PA: Popliteal Artery; PM: Psoas Muscle; PTA: Posterior Tibial Artery; SP: Spondylitis; TA:
Thoracic Aorta.
b CM: Largest Diameter in Centimeters; NA: Not Applicable; NR: Not reported.
c AP: Abdominal Pain; LBP: Low Back Pain(Lumbago); NS: Night Sweats; RDP: Radiculopathy; WL: Weight Loss.
d EVAR: Endovascular Repair.
e E: Ethambutol; FQ: Fluoroquinolone; I: Isoniazid; R: Rifampin.
f Immunotherapy for Malignant Melanom.
g Case previously tabulated by Coscas et. al.
h Not further specified.
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While data regarding evaluation and management are lim-
ited, this report is the most comprehensive review to date.
Based on characteristics of previous cases, it is recommended
that any individual with a history of BCG instillation therapy
who subsequently develops sustained constitutional symp-
toms, including new-onset lumbago, should be evaluated for
the presence of mycotic aneurysm. Additionally, surgical
evaluation and medical management with 2 months of isoni-
azid, rifampin, and ethambutol followed by a minimum of
7 months of isoniazid and rifampin seems prudent.Conflicts of interest
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